Jasper Therapeutics JSPR
NASDAQ JSPR
$0.50 +0.00 (+0.00%)
At close: Oct 22, 2026 · 4:00 PM EDT

Jasper Therapeutics (JSPR) Accumulated Expenses (2020 - 2023)

Updated

Jasper Therapeutics (JSPR) posted Accumulated Expenses of $100,000 for Q2 2023, down 96.5% from $2.84 million a year earlier.

Analysis

Jasper Therapeutics (JSPR) Accumulated Expenses (2020 - 2023) Analysis & Trends

At the end of FY2022, Jasper Therapeutics' Accumulated Expenses came in at $4.43 million, up 23.2% from FY2021.

  • In prior years, Jasper Therapeutics' Accumulated Expenses was $3.6 million in FY2021 (+38.6%) and $2.6 million in FY2020.
  • The Q2 2023 figure stands as the lowest quarterly Accumulated Expenses in data going back to Q4 2020.
  • On a year-over-year basis, Accumulated Expenses increased in two of the last four quarters, with an average decline of 20.2%.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 Jasper Therapeutics 14.04 Mn -112.38 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 100,000.00
Dec 31, 2022 4.43 Mn
Sep 30, 2022 3.46 Mn
Jun 30, 2022 2.84 Mn
Mar 31, 2022 3.98 Mn
Dec 31, 2021 3.60 Mn
Sep 30, 2021 8.92 Mn
Dec 31, 2020 2.60 Mn
API Access

Jasper Therapeutics Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=JSPR&period=max&api_key=YOUR_API_KEY